Investor Presentation 2023

LONG-TERM REVENUE GROWTH ASSUMPTIONS (As of May 2021 Investor Day) End Markets Aerospace Defense ORGANIC REVENUE CAGR (2021-2023) LSD (up 22% in '20); On track; Stable growth on key platforms LSD; Easing of supply chain challenges (electronic components) Ground Defense Org (LSD) + PacStar (HSD); Easing of supply chain challenges (electronic components) Naval Defense Comm'l Aerospace Power & Process General Industrial Total CW Sales Growth MSD (Expect narrowbody recovery end of 2023; Widebody by end 2025); Full recovery more likely by 2025+ Nuclear: LSD (Excluding new AP1000 orders); On track to reach in 2023 Process: MSD-HSD (Expect full recovery by 2023); Achieved in 2022 Industrial Vehicles: HSD (Expect full recovery by 2022); Achieved in 2021 Industrial Automation and Services: MSD; Line of sight to reach in 2023 Base (Organic + PacStar): Min. 5% CAGR; On track to Exceed Organic: 3-5% CAGR; On track to Exceed CURTISS- WRIGHT Note: LSD, MSD and HSD represent low-single digit, mid-single digit and high-single digit, respectively; PacStar acquired October 2020; Long-term guidance does not include any contribution from the arresting systems business acquisition. Investor Presentation 2023 30

View entire presentation